| 【英語タイトル】Global PEGylated Proteins Market Size study & Forecast, by Protein Type (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII, Others), by Product & Services (Consumables, Services), by Application (Cancer, Autoimmune diseases, Hepatitis, Multiple sclerosis, Hemophilia, Gastrointestinal disorders, Others), by End-User (Pharmaceutical & biotechnology companies, Contract research organizations, Academic & research institutes), and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23FE0039
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年1月29日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：化学
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社発行の本調査レポートによると、2021年に11.4億ドルであった世界のPEG化タンパク質市場規模が、2022年から2029年の間に11.71%成長すると予想されます。本書は、PEG化タンパク質の世界市場を総合的に分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、タンパク質種類別（コロニー刺激因子、インターフェロン、エリスロポエチン、組換え第VII因子、その他）分析 、製品＆サービス別（消耗品、サービス）分析、用途別（癌、自己免疫疾患、肺炎、多発性硬化症、その他）分析、エンドユーザー別（製薬・バイオテクノロジー企業、受託研究機関、学術・研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争分析、調査プロセスなど、多面的な分析結果を掲載しています。なお、参入企業情報として、Thermo Fisher Scientific, Inc.、Abcam plc.、Enzon Pharmaceuticals, Inc.、Merck KGaA、Celares GmbH、Profacgen、Creative PEGworks、NOF America Corp.、Aurigene Pharmaceutical Services Ltd.、Laysan Bio, Inc.などが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界のPEG化タンパク質市場規模：タンパク質種類別
- コロニー刺激因子の市場規模
- インターフェロンの市場規模
- エリスロポエチンの市場規模
- 組換え第VII因子の市場規模
- その他の市場規模
・世界のPEG化タンパク質市場規模：製品＆サービス別
- 消耗品の市場規模
- サービスの市場規模
・世界のPEG化タンパク質市場規模：用途別
- 癌における市場規模
- 自己免疫疾患における市場規模
- 肺炎における市場規模
- 多発性硬化症における市場規模
- その他における市場規模
・世界のPEG化タンパク質市場規模：エンドユーザー別
- 製薬・バイオテクノロジー企業における市場規模
- 受託研究機関における市場規模
- 学術・研究機関における市場規模
・世界のPEG化タンパク質市場規模：地域別
- 北米のPEG化タンパク質市場規模
- ヨーロッパのPEG化タンパク質市場規模
- アジア太平洋のPEG化タンパク質市場規模
- 中南米のPEG化タンパク質市場規模
- その他地域のPEG化タンパク質市場規模
・競争分析
・調査プロセス |
Global PEGylated Proteins Market is valued at approximately USD 1.14 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.71% over the forecast period 2022-2029. PEGylation is a method of altering or binding biological molecules by coupling with polyethylene glycol. PEGylation helps in improving the stability and solubility of the drug, along with it reduces immunogenicity by altering the electrostatic binding, confirmation, and hydrophobicity of the molecule. The market growth is primarily driven by the factors such as rising consumption of protein-based drugs, increasing inclination towards protein treatments, coupled with the development of the biologics sector
The rising prevalence of chronic diseases such as cancer, autoimmune diseases, hepatitis, gastrointestinal disorders, etc. is stipulating the demand for PEGylated Proteins in the global market. According to National Cancer Institute, the number of cancer patients is expected to rise to 29.5 million cases, by the year 2040 from 18.1 million cases, in the year 2018. Accordingly, the high incidences of cancer are fostering the demand for PEGylated proteins in cancer therapy accelerating the growth of the market. In addition, the growing investment in the R&D of biologics, as well as the high presence of strong pipeline drugs are presenting various growth prospects to the market over the forecasting years. However, the high cost of the production process for PEGylation and patent expiration for novel PEGylated biologics are hampering the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global PEGylated Proteins Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness regarding advanced therapeutics, increasing incentives to advance healthcare plans and the presence of key players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the presence of a huge population base, surging demand for proteins-based drugs, and the increased government funds in the regional market.
Major market players included in this report are:
Thermo Fisher Scientific, Inc.
Abcam plc.
Enzon Pharmaceuticals, Inc.
Merck KGaA
Celares GmbH
Profacgen
Creative PEGworks
NOF America Corp.
Aurigene Pharmaceutical Services Ltd.
Laysan Bio, Inc.
Recent Developments in the Market:
In February 2022, Merck KGaA unveils the acquisition of Exelead- a full-service biopharmaceutical CDMO for USD 780 million with the objective of expanding the company’s mRNA and lipid capabilities. Merck KGaA also declared that it has intend to invest more than USD 485.67 to augment the technologies.
Global PEGylated Proteins Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Protein Type, Product & Services, Application, End-User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Protein Type:
Colony-stimulating factor
Interferons
Erythropoietin
Recombinant factor VII
Others
By Product & Services:
Consumables
Services
By Application:
Cancer
Autoimmune diseases
Hepatitis
Multiple sclerosis
Hemophilia
Gastrointestinal disorders
Others
By End-User:
Pharmaceutical & biotechnology companies
Contract research organizations
Academic & research institutes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. PEGylated Proteins Market, by Region, 2019-2029 (USD Billion)
1.2.2. PEGylated Proteins Market, by Protein Type, 2019-2029 (USD Billion)
1.2.3. PEGylated Proteins Market, by Product & Services, 2019-2029 (USD Billion)
1.2.4. PEGylated Proteins Market, by Application, 2019-2029 (USD Billion)
1.2.5. PEGylated Proteins Market, by End-User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global PEGylated Proteins Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global PEGylated Proteins Market Dynamics
3.1. PEGylated Proteins Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising consumption of proteins-based drugs
3.1.1.2. Rising prevalence of chronic diseases
3.1.2. Market Challenges
3.1.2.1. High cost of the production process for PEGylation
3.1.2.2. Patent expiration for novel PEGylated biologics
3.1.3. Market Opportunities
3.1.3.1. Growing investment in the R&D of biologics
3.1.3.2. High presence of strong pipeline drugs
Chapter 4. Global PEGylated Proteins Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global PEGylated Proteins Market, by Protein Type
6.1. Market Snapshot
6.2. Global PEGylated Proteins Market by Protein Type, Performance – Potential Analysis
6.3. Global PEGylated Proteins Market Estimates & Forecasts by Protein Type 2019-2029 (USD Billion)
6.4. PEGylated Proteins Market, Sub Segment Analysis
6.4.1. Colony-stimulating factor
6.4.2. Interferons
6.4.3. Erythropoietin
6.4.4. Recombinant factor VII
6.4.5. Others
Chapter 7. Global PEGylated Proteins Market, by Product & Services
7.1. Market Snapshot
7.2. Global PEGylated Proteins Market by Product & Services, Performance – Potential Analysis
7.3. Global PEGylated Proteins Market Estimates & Forecasts by Product & Services 2019-2029 (USD Billion)
7.4. PEGylated Proteins Market, Sub Segment Analysis
7.4.1. Consumables
7.4.2. Services
Chapter 8. Global PEGylated Proteins Market, by Application
8.1. Market Snapshot
8.2. Global PEGylated Proteins Market by Application, Performance – Potential Analysis
8.3. Global PEGylated Proteins Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
8.4. PEGylated Proteins Market, Sub Segment Analysis
8.4.1. Cancer
8.4.2. Autoimmune diseases
8.4.3. Hepatitis
8.4.4. Multiple sclerosis
8.4.5. Hemophilia
8.4.6. Gastrointestinal disorders
8.4.7. Others
Chapter 9. Global PEGylated Proteins Market, by End-User
9.1. Market Snapshot
9.2. Global PEGylated Proteins Market by End-User, Performance – Potential Analysis
9.3. Global PEGylated Proteins Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
9.4. PEGylated Proteins Market, Sub Segment Analysis
9.4.1. Pharmaceutical & biotechnology companies
9.4.2. Contract research organizations
9.4.3. Academic & research institutes
Chapter 10. Global PEGylated Proteins Market, Regional Analysis
10.1. PEGylated Proteins Market, Regional Market Snapshot
10.2. North America PEGylated Proteins Market
10.2.1. U.S. PEGylated Proteins Market
10.2.1.1. Protein Type breakdown estimates & forecasts, 2019-2029
10.2.1.2. Product & Services breakdown estimates & forecasts, 2019-2029
10.2.1.3. Application breakdown estimates & forecasts, 2019-2029
10.2.1.4. End-User breakdown estimates & forecasts, 2019-2029
10.2.2. Canada PEGylated Proteins Market
10.3. Europe PEGylated Proteins Market Snapshot
10.3.1. U.K. PEGylated Proteins Market
10.3.2. Germany PEGylated Proteins Market
10.3.3. France PEGylated Proteins Market
10.3.4. Spain PEGylated Proteins Market
10.3.5. Italy PEGylated Proteins Market
10.3.6. Rest of Europe PEGylated Proteins Market
10.4. Asia-Pacific PEGylated Proteins Market Snapshot
10.4.1. China PEGylated Proteins Market
10.4.2. India PEGylated Proteins Market
10.4.3. Japan PEGylated Proteins Market
10.4.4. Australia PEGylated Proteins Market
10.4.5. South Korea PEGylated Proteins Market
10.4.6. Rest of Asia Pacific PEGylated Proteins Market
10.5. Latin America PEGylated Proteins Market Snapshot
10.5.1. Brazil PEGylated Proteins Market
10.5.2. Mexico PEGylated Proteins Market
10.5.3. Rest of Latin America PEGylated Proteins Market
10.6. Rest of The World PEGylated Proteins Market
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Thermo Fisher Scientific, Inc.
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Abcam plc.
11.2.3. Enzon Pharmaceuticals, Inc.
11.2.4. Merck KGaA
11.2.5. Celares GmbH
11.2.6. Profacgen
11.2.7. Creative PEGworks
11.2.8. NOF America Corp.
11.2.9. Aurigene Pharmaceutical Services Ltd.
11.2.10. Laysan Bio, Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption
